drugset / Trial / NCT06610773

HUC-MSC for Treatment of High-risk HPV Infection

NCT06610773

Phase 1/2 Recruiting 60 enrolled Shanghai East Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the safety and initial effectiveness of human umbilical cord mesenchymal stem cells in HPV clearance.

Timeline

Start
2024-03-01
Primary completion
2025-09-10
Completion
2026-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject human umbilical cord mesenchymal stem cells Cell therapy 1 cells/kg Intravenous